Endoscopic and histopathologic features of Anti-PD-1-related collagenous colitis

Hidezumi Kikuchi1,2 | Hirotake Sakuraba1 | Yui Akemoto3 | Kazuhiro Hosoi4 | Yasuhisa Murai1 | Kentaro Hoshi1 | Yukari Fukutoku1 | Taka Asari1 | Yohei Sawada1 | Keisuke Hasui1 | Tetsuya Tatsuta1 | Hiroto Hiraga1 | Daisuke Chinda1 | Tatsuya Mikami5 | Shinsaku Fukuda1

1 Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Aomori, Japan
2 Department of Community Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan
3 Department of Anatomic Pathology, Hirosaki University Hospital, Aomori, Japan
4 Department of Pharmacy, Hirosaki University Hospital, Aomori, Japan
5 Innovation Center for Health Promotion, Hirosaki University Graduate School of Medicine, Aomori, Japan

Correspondence
Hidezumi Kikuchi, Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, Aomori 036-8562, Japan. Email: hidezumi@hirosaki-u.ac.jp

Abstract

Objectives: Cancer patients treated with immune checkpoint inhibitors occasionally show persistent diarrhea accompanied by endoscopic features of ulcerative colitis. The endoscopic mucosal inflammation may appear mild in some patients compared to the clinical severity, which can make choosing a treatment challenging. In this study, we evaluated the factors that support the continuation of chemotherapy by assessing the endoscopic and histopathological characteristics of patients who experienced diarrhea after immune checkpoint inhibitor administration.

Methods: This study included eight patients who were diagnosed with collagenous colitis based on pathological assessments. We retrospectively investigated these patients’ backgrounds, laboratory data, and computed tomography images that were extracted from their medical records. We also summarized their endoscopic and pathologic findings.

Results: All eight patients were being treated with anti-programmed cell death-1/programmed cell death-ligand 1 therapeutic agents and had a recent history of oral proton pump inhibitor therapy. The anti-programmed cell death-1-related collagenous colitis in these cases was characterized by endoscopically mild mucosal inflammation, high fecal calprotectin levels, and a lower frequency of intestinal wall thickening on computed tomography. Histological assessments showed CD8+ lymphocytes predominantly infiltrating the lamina propria and crypts of the colonic mucosa. Suspending the proton pump inhibitor therapy relieved the patients’ symptoms and allowed the continuation of the anti-programmed cell death-1/programmed cell death-ligand 1 therapy.

Conclusions: Anti-programmed cell death-1-related collagenous colitis is reversible; appropriate diagnosis of adverse events is crucial for the continuation of immune checkpoint inhibitor therapy.

KEYWORDS
CD8-positive T-lymphocytes, collagenous colitis, diarrhea, immune checkpoint inhibitor, proton pump inhibitor

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society

DEN Open. 2022;2:e92. https://doi.org/10.1002/deo2.92
INTRODUCTION

Immune checkpoint inhibitors (ICIs) are approved for the treatment of various types of cancers; however, immune-related adverse events (irAEs) are a major problem associated with ICI treatments.\textsuperscript{1} Colitis is a common gastrointestinal irAE\textsuperscript{2,3} and although the pathogenic mechanisms underlying colitis presenting as an irAE remain unknown, the endoscopic features resemble those of ulcerative colitis.\textsuperscript{4–7} There are two types of irAE colitis: active and lymphocytic.\textsuperscript{2,3,8} Symptomatic therapy or suspension of ICIs is effective for treating mild colitis manifesting as an irAE; however, severe cases require administration of steroids or biologics, such as infliximab.\textsuperscript{5} Early intervention can be key to enable continued chemotherapy for patients with colitis. Unfortunately, creating a medical plan for ICI-related diarrhea with poor endoscopic findings may be difficult.

A few reports have described collagenous colitis (CC) development after ICI treatments; however, the underlying mechanisms and clinical features remain unclear.\textsuperscript{9–11} irAEs resulting from an ICI treatment can systemically affect several organs, and thus, involvement of a single inflammatory mechanism may be unlikely.\textsuperscript{12} The intestinal immune system crosstalk is particularly complex and controversial. Therefore, the etiology of colitis manifesting as an irAE has not yet been fully clarified. In this study, we collected data from patients who developed CC after undergoing anti-programmed cell death-1 (anti-PD-1)/programmed cell death-ligand 1 (PD-L1) treatments at a single institution and examined the endoscopic and pathological characteristics associated with anti-PD-1-related CC.

METHODS

Patients

Endoscopic imaging and histopathological evaluations of colonic mucosal biopsies were performed from January 2016 to December 2020 for every patient who visited our department presenting with diarrhea after undergoing ICI treatment. We included patients diagnosed with CC in this study; patients' clinical information related to age, sex, medical history, diarrhea severity, type of ICI, period from ICI administration to symptom onset, and concomitant medications was retrospectively extracted from the medical records. Diarrhea severity was graded using the Common Terminology Criteria for Adverse Events version 5.0 (National Cancer Institute/National Institute of Health, Bethesda, MD, USA).\textsuperscript{13} Laboratory data, including C-reactive protein (CRP) and fecal calprotectin (FC) levels and results of fecal immunochemical test (FIT), were obtained, and contrast-enhanced computed tomography (CT) images during the symptomatic diarrhea period were acquired before patient colonoscopy.

Additionally, to compare CC features with or without ICI treatment, data for nine patients with ICI-independent traditional CC (T-CC) were extracted from a pathology database at our institution.

Colonoscopy

A colonoscopy was performed for each patient within 4 days of their first visit to our department. Loss of vascularity, erythema, granularity, erosion, and ulcers was defined as endoscopic mucosal changes. Biopsies from each colon segment (i.e., cecum, ascending colon, transverse colon, descending colon, and sigmoid colon) and the rectum were performed for six patients. The colonoscope was inserted into the transverse colon of one patient due to poor bowel preparation; subsequently, biopsy specimens were collected from the transverse colon to the rectum. Biopsy specimens could not be collected from the cecum and ascending colon of another patient who had undergone a right hemicolectomy.

Pathological evaluation

CC was defined by a subepithelial collagen band thickness >10 µm using Masson’s trichrome staining. A tissue architecture assessment using hematoxylin and eosin staining and simple mucosal biopsy criteria was required to exclude inflammatory bowel disease (IBD).\textsuperscript{14} We investigated T-lymphocyte infiltration into the colorectal mucosa using immunohistochemistry with the following antibodies: CD3 (prediluted; Leica Biosystems, Wetzlar, Germany), CD4 (1:4 dilution; Nichirei Corporation, Tokyo, Japan), and CD8 (1:150 dilution; Nichirei Corporation, Tokyo, Japan). We enumerated CD3\textsuperscript{−}, CD4\textsuperscript{−}, and CD8-positive T cells per 200× magnification field-of-view.

Statistical analysis

Statistical analyses were performed using a Mann–Whitney test (GraphPad Prism 9.0.2; GraphPad Software, San Diego, CA, USA).

RESULTS

Clinical characteristics

During the study period, 18 patients visited our department reporting diarrhea after ICI administration; eight were diagnosed with CC based on subepithelial collagen band deposition >10 µm. The differential
TABLE 1  Patient characteristics

| Case | Age | Sex | Original cancer | Symptom | CTCAE (grade) | Drug | Time between start of ICI and diarrhea (weeks) | Concomitant drugs | Time between start of drugs and diarrhea (weeks) | Other drugs |
|------|-----|-----|-----------------|---------|---------------|------|-----------------------------------------------|-------------------|-----------------------------------------------|------------|
| 1    | 78  | F   | NSCLC           | Diarrhea | 2             | Niv  | 59                                            | Lansoprazole      | 201                                           | Olanzapine, zolpidem, magnesium oxide |
| 2    | 57  | M   | Esophageal cancer | Diarrhea | 1             | Niv  | 109                                           | Lansoprazole      | 117                                           | Bromhexine hydrochloride, Hochuekkito |
| 3    | 65  | M   | NSCLC           | Diarrhea | 2             | Dur  | 300                                          | Lansoprazole      | 1313                                          | Clonazepam, tapentadol hydrochloride, pregabalin, codeine phosphate |
| 4    | 83  | M   | Renal cell carcinoma | Diarrhea | 2             | Niv-Ipi | 3                                      | Esomeprazole, naproxen | 42                                | Nifedipine, valsartan, brotizolam, glimepiride amiodpine besilate, |
| 5    | 83  | F   | Urothelial carcinoma | Diarrhea | 3             | Pem  | 23                                            | Esomeprazole      | 35                                            | Atorvastatin, nifedipine, carbazochrome sodium sulfate hydrate |
| 6    | 74  | M   | NSCLC           | Diarrhea | 2             | Niv  | 16                                            | Lansoprazole      | 604                                           | Allopurinol, dutasteride, silodosin, tapentadol hydrochloride |
| 7    | 71  | M   | NSCLC           | Diarrhea | 2             | Pem  | 37                                            | Lansoprazole      | 17                                            | Fexofenadine hydrochloride |
| 8    | 82  | F   | Malignant lymphoma | Diarrhea | 2             | Niv  | 6                                             | Lansoprazole      | 116                                           | Edoxaban tosylate hydrate, bisoprolol |

Abbreviations: PPI, proton pump inhibitor; CTCAE, Common Terminology Criteria for Adverse Events; NSCLC, non-small cell lung cancer; ICI, immune checkpoint inhibitor; Niv, nivolumab; Dur, durvalumab; Ipi, ipilimumab; Pem, pembrolizumab.

diagnoses for these patients were made based on the exclusion of other types of infectious colitis through fecal bacterial culture, *Clostridium difficile* toxin test, and by the absence of endoscopic and histological findings for cytomegalovirus or tuberculosis infections. The remaining 10 patients were diagnosed with irAE colitis (n = 4), irAE ileitis (n = 1), *C. difficile* infection (n = 1), eosinophilic colitis (n = 1), nonspecific colitis (n = 1), and nonspecific ileitis (n = 2). The irAE colitis diagnoses were based on histopathological colitis patterns, characterized by neutrophilic inflammation and prominent intestinal epithelial cell apoptosis, in the presence of anti-PD-1 therapy.15 None of the patients met the diagnostic criteria for lymphocytic colitis or IBD.

The clinical characteristics of the patients are summarized in Table 1. There were five men and three women with a median age of 76 years (range, 57–83 years) and a variety of oncological backgrounds. All the patients received anti-PD-1/PD-L1 antibody therapy. Seven patients underwent ICI monotherapy, with nivolumab (n = 4), pembrolizumab (n = 2), or durvumab (n = 1). One patient underwent nivolumab plus ipilimumab combination therapy. None of the patients had hematochezia. Surprisingly, all the patients were taking oral proton pump inhibitors (PPIs), including lansoprazole (n = 6), and esomeprazole (n = 2). Four patients also received analgesic drugs, non-steroidal anti-inflammatory drugs (naproxen), acetaminophen, or codeine phosphate.

**Endoscopic and histological findings**

The endoscopic and histological findings for anti-PD-1-related CC (n = 8), irAE colitis (n = 4), irAE ileitis (n = 1), and T-CC (n = 9) are summarized in Table 2. Notably, all patients with anti-PD-1-related CC showed indistinctness or loss of vascularity in the colorectal mucosa (Figure 1). Linear erosions similar to those of T-CC
| Diagnosis                                | Case | Colonoscopy Loss of vascularity | Colonoscopy Erythema | Colonoscopy Granularity | Colonoscopy Erosion | Colonoscopy Ulcer | Histology Acute inflammation | Histology Cryptitis | Histology Crypt abscess | Histology Apoptosis | Collagen band (µm) |
|-----------------------------------------|------|---------------------------------|----------------------|-------------------------|---------------------|------------------|-----------------------------|---------------------|------------------------|---------------------|---------------------|
| ICI-associated enterocolitis            | 1    | ±                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | −                   |
| Anti-PD-1-related CC                    | 2    | ±                              | −                    | −                       | −                   | −                | +                          | +                   | −                      | −                   | 30                  |
|                                         | 3    | +                              | −                    | −                       | −                   | −                | +                          | +                   | −                      | −                   | 29                  |
|                                         | 4    | +                              | +                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 12                  |
|                                         | 5    | +                              | +                    | −                       | −                   | −                | −                          | −                   | +                      | −                   | 12                  |
|                                         | 6    | +                              | −                    | −                       | −                   | −                | +                          | +                   | −                      | +                   | 23                  |
|                                         | 7    | ±                              | −                    | −                       | −                   | −                | +                          | +                   | −                      | +                   | 25                  |
|                                         | 8    | +                              | −                    | −                       | −                   | −                | +                          | +                   | −                      | +                   | 49                  |
| irAE colitis                            | 9    | +                              | +                    | +                       | −                   | −                | +                          | +                   | +                      | +                   | −                   |
|                                         | 10   | +                              | +                    | +                       | −                   | −                | +                          | +                   | +                      | +                   | −                   |
|                                         | 11   | ±                              | +                    | −                       | −                   | −                | +                          | +                   | −                      | +                   | −                   |
|                                         | 12   | +                              | +                    | +                       | +                   | +                | +                          | +                   | +                      | −                   | −                   |
|                                         | 13   | +                              | +                    | +                       | +                   | +                | +                          | +                   | +                      | −                   | −                   |
| ICI-independent traditional CC          | 14   | ±                              | −                    | −                       | −                   | −                | +                          | +                   | +                      | −                   | 22                  |
| (T-CC)                                  | 15   | ±                              | +                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 41                  |
|                                         | 16   | ±                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | +                   | 35                  |
|                                         | 17   | ±                              | +                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 70                  |
|                                         | 18   | −                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | +                   | 50                  |
|                                         | 19   | −                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 40                  |
|                                         | 20   | ±                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 28                  |
|                                         | 21   | −                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 30                  |
|                                         | 22   | −                              | −                    | −                       | −                   | −                | −                          | −                   | −                      | −                   | 15                  |

Abbreviations: anti-PD-1, anti-programmed cell death-1; CC, collagenous colitis; irAE, immune-related adverse events.
Case 1: A 78-year-old woman with non-small cell lung cancer developed diarrhea 58 weeks after beginning treatment with nivolumab. (a) A colonoscopy revealed an indistinct vascular pattern. (b,c) Collagen bands were deposited in the biopsy specimen from the sigmoid colon.

Case 5: An 83-year-old man with renal cell carcinoma developed diarrhea 3 weeks after beginning nivolumab and ipilimumab combination therapy. (a) A colonoscopy revealed a loss of vascularity and linear erosion (arrow). (b,c) Collagen bands were deposited in the sigmoid colon.

Case 8: An 81-year-old woman with malignant melanoma developed diarrhea 8 weeks after beginning treatment with nivolumab. (a) Normal mucosa was observed in the first colonoscopy, prior to the anti-programmed cell death-1 (anti-PD-1) treatment. (b) Loss of vascularity and erosion were seen in the second colonoscopy, after the anti-PD-1 treatment began.

Collagen bands were observed in three patients (Figure 2). None of the patients showed ulcers or hemorrhages in the colon or rectum. Interestingly, for patient #8, a colonoscopy prior to the induction of the anti-PD-1 treatment showed no mucosal changes. However, colonic mucosal changes, such as a loss of vascularity and erosion, were detected after anti-PD-1 administration, accompanied by persistent diarrhea (Figure 3).

In the histopathological evaluations, collagen bands >10 μm were observed in the subepithelial layer for all the patients with anti-PD-1-related CC and T-CC. Collagen bands were visible in the sigmoid, transverse, and ascending colons of most of the patients with anti-PD-1-related CC (Table 3, shaded area). Moreover, two patients had anti-PD-1-related collagenous ileitis. In five of the anti-PD-1-related CC cases, apoptotic bodies were observed in the crypts (Figure 4). Interestingly, most of the apoptotic bodies were found in the colorectal segments in which a collagen band was seen (Table 3, shaded area and "Apo").

Immunohistochemical analysis showed that most of the infiltrated inflammatory cells around the collagen band were CD3+ cells, suggesting that these inflammatory cells were primarily of T-cell lineage. Moreover, the infiltration by CD8+ cells, which were localized in the subepithelial layer, was more compared to CD4+...
TABLE 3 Distribution of collagen band and presence of apoptosis

| Case | R  | S   | D  | T  | A  | C   | I    |
|------|----|-----|----|----|----|-----|------|
| 1    | –  | –   | –  | –  | –  | –   | –    |
| 2    | Apo| Apo | –  | –  | n/a| n/a | n/a  |
| 3    | –  | –   | –  | –  | –  | –   | –    |
| 4    | –  | –   | –  | –  | –  | –   | –    |
| 5    | Apo| –   | Apo| –  | –  | –   | –    |
| 6    | Apo| Apo | Apo| Apo| Apo| Apo | –    |
| 7    | –  | Apo | –  | –  | –  | –   | Apo  |
| 8    | –  | Apo | Apo| Apo| Apo| Post rt. hemicolectomy | –    |

Abbreviations: R, rectum; S, sigmoid colon; D, descending colon; T, transverse colon; A, ascending colon; C, cecum; I, ileum; n/a, not available.

Shaded areas signify the segments where a collagen band was seen.

Apo apoptotic body were detected in biopsy specimens from “Apo” segment.

FIGURE 4 Case 4: An 83-year-old woman with renal cell carcinoma developed diarrhea 20 weeks after beginning pembrolizumab therapy. (a) A colonoscopy revealed a loss of vascularity and rough-surfaced mucosa. (b) Apoptotic bodies were seen in the crypts (arrow). (c) Collagen bands were deposited in the descending colon.

Clinical course

The clinical course of the patients is summarized in Table 5. In the short term, the anti-PD-1/PD-L1 treatment could be continued with suspension of the PPI for seven patients with mild disease. We performed colonoscopy and biopsies for one patient after the PPI was discontinued, post which the collagen band histologically disappeared (Figure 6). The patient with severe disease, who had to cease the ICI treatment, required intravenous prednisolone (PSL) administration; however, the patient died 6 months after anti-PD-1-related CC diagnosis due to cancer progression. In the long-term follow-up, two patients were able to continue the ICI treatment for advanced cancer.

DISCUSSION

To the best of our knowledge, this is the first report describing a series of patients who developed CC after being treated with ICIs. Our data show that CC was one of the most latent diseases in the patients presenting with diarrhea after anti-PD-1/PD-L1 treatment. Although the patients’ endoscopic anti-PD-1-related CC...
features could be obscure, with only mild colorectal mucosa inflammation, the pathological evaluations suggest that anti-PD-1-related CC was characterized by dominant infiltration of CD8+ cells with localization into the crypts.

The etiology of CC remains controversial. Previous clinical studies have suggested certain risk factors for T-CC, including genetic predisposition, immune disorders, gut microbiota, medications, and age.16–20 PPIs are well-known inducers of CC.21 Conversely, the ICI-related colitis risk factors include repeated ICI administration cycles, concomitant medications, a history of IBD, gut microbiota, and malignant melanoma.22–24

TABLE 4 Inflammatory biomarker levels and colorectal wall thickness on CT image

| Case | CRP (mg/dl) | FC (µg/g) | FIT (ng/ml) | Colorectal wall thickness on CT image |
|------|-------------|-----------|-------------|--------------------------------------|
| 1    | 1.9         | n/a       | n/a         | n/a                                  |
| 2    | 0.663       | 3380      | 102         | –                                    |
| 3    | 8.159       | 11500     | 3369        | Low                                  |
| 4    | 1.536       | 718       | 57          | n/a                                  |
| 5    | 6.155       | n/a       | n/a         | low                                  |
| 6    | 2.21        | 5720      | 215         | –                                    |
| 7    | 1.7         | 107       | 66          | low                                  |
| 8    | 5.56        | 4244      | 2431        | –                                    |

Abbreviations: CT, computed tomography; CRP, C-reactive protein; FC, fecal calprotectin; FIT, fecal immunochemical test; n/a, not available.
TABLE 5 Clinical course

| Case | Gastric acid inhibitor | Cancer treatment after diagnosis of anti-PD-1 related CC | Outcome | Cause of death | Follow-up period (week) |
|------|------------------------|--------------------------------------------------------|---------|----------------|------------------------|
| 1    | Discontinuation ICI    | Change to chemotherapy                                   | Alive   |                 | 161                    |
| 2    | Change to VPZ ICI      | Continuation of ICI                                     | Alive   |                 | 143                    |
| 3    | Change to VPZ stop     | Best supportive care                                    | Death   | Cancer progression | 24                |
| 4    | Discontinuation ICI    | Discontinuation of ICI due to irAE hepatitis            | Death   | Hepatic failure | 3                      |
| 5    | Discontinuation ICI    | Discontinuation of ICI due to cancer progression        | Death   | Cancer progression | 83                |
| 6    | Change to VPZ ICI      | Continuation of ICI                                     | Alive   |                 | 54                     |
| 7    | Change to FA ICI       | Discontinuation of ICI due to irAE skin disorders       | Alive   |                 | 44                     |
| 8    | Change to FA ICI       | Discontinuation of ICI due to cancer progression        | Death   | Cancer progression | 44                |

Abbreviations: VPZ, vonoprazan fumarate; FA, famotidine; anti-PD-1, anti-programmed death-1; CC, collagenous colitis; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event.

FIGURE 6 (a) Case 7: A 71-year-old man with non-small cell lung cancer developed diarrhea 14 weeks after beginning pembrolizumab therapy. Indistinct vascularity was seen in the first colonoscopy image, while collagen deposits were detected histologically. (b) The second colonoscopy was performed after the proton pump inhibitor treatment was discontinued and the collagen band was no longer present in the biopsy specimen.

We reviewed 11 publications that described irAE colitis case series and minireviews. Detailed pathological investigations showed five cases of CC after an anti-PD-1/PD-L1 treatment. We also reviewed three case reports describing this diagnosis. Although some data (such as endoscopically evident mucosal change, histological findings, concomitant drug use, or long-term follow-up outcomes) were unavailable, each of the three patients was reportedly treated for CC with budesonide or PSL. Thus, there remains no consensus regarding the importance of anti-PD-1/PD-L1 antibody agents as risk factors for CC. In our study, eight patients with a recent medical history of PPIs developed CC after an additional treatment with anti-PD-1/PD-L1 agents. Therefore, we argue that anti-PD-1/PD-L1 antibody therapy could be a risk factor for CC in patients undergoing PPI therapy. The endoscopic features of anti-PD-1-related CC are characterized by mild inflammatory changes, even in patients suffering from severe diarrhea. In the present study, the most frequent colonoscopy finding was mucosal cloudiness, while erythema, granularity, and ulcer findings were relatively minor compared to those observed in typical irAE active colitis.
A histopathological anti-PD-1-related CC diagnosis is based on the deposition of a subepithelial collagen band >10 μm. In the present study, the collagen band distribution showed that anti-PD-1-related CC was not left-side dominant, and had potential to extend to the ileum. Additionally, in the patients with anti-PD-1-related CC, the crypts were predominantly infiltrated by CD8+ lymphocytes, rather than CD4+ lymphocytes. Göranzon et al. found a predominant accumulation of CD8+ lymphocytes in both the epithelium and lamina propria in patients with microscopic colitis, including those with CC and lymphocytic colitis.32 Another group found CD8+ T cells in the lamina propria and epithelium in patients with anti-PD-1-induced colitis.28

Apoptotic bodies are often detected in the crypt in patients with PD-1-induced active colitis.2,15,30 In our study, in patients with anti-PD-1-related CC, most of the apoptotic bodies were in the colorectal segments where collagen bands were observed. Anti-PD-1-related CC was similar to T-CC in terms of the presentation of the collagen band and predominant infiltration of CD8+ cells into the lamina propria, but differed in terms of the subepithelial cellularity and CD8+ cell infiltration into the crypt. In contrast, anti-PD-1-related CC was similar to anti-PD-1-induced active colitis in terms of the predominant CD8+ infiltration and increasing apoptotic body levels in the crypt, although the two diseases differed in terms of the collagen deposits. In other words, our patients with anti-PD-1-related CC displayed features of both T-CC and anti-PD-1-induced active colitis.

Our findings indicate two clinical features of anti-PD-1-related CC. The first is the lower incidence of intestinal wall thickening on CT images. The intestinal wall thickness, as measured on CT images, is a key factor to consider when assessing the severity and extent of active colitis due to irAE.33 Therefore, the absence of an increase in the intestinal wall thickness on CT images in patients with diarrhea after ICI treatment may be suggestive of anti-PD-1-related CC, rather than active colitis due to irAE. To confirm the diagnosis of anti-PD-1-related CC, a pathological examination following a colonoscopy and biopsy is essential.

The second key clinical feature of anti-PD-1-related CC was the elevated FC levels. Calprotectin is a calcium-binding protein primarily secreted by neutrophils and activated macrophages.34 FC is a clinical marker that shows high sensitivity and specificity for intestinal inflammation, especially in IBD; it is also useful as a biomarker for T-CC.35 In the present study, the FC levels were increased in all patients with anti-PD-1-related CC, including those who were FIT-negative. However, because FC is not specific to CC, it cannot be used to distinguish anti-PD-1-related CC from typical irAE colitis. Elevated FC levels indicate the presence of inflammation, which is found in both anti-PD-1-related CC and irAE colitis. Therefore, an endoscopic examination is recommended for patients with elevated FC levels to distinguish anti-PD-1-related CC from irAE colitis, even if the colorectal wall thickness is not increased on CT images. At the time of the initial diagnosis, the FC levels are not related to the diarrhea severity, endoscopic changes, number of infiltrated inflammatory cells, or collagen band thickness. However, after diagnosis of anti-PD-1-related CC based on histological assessments, we believe that FC measurement might be useful as a non-invasive biomarker of disease activity during follow-up anti-PD-1-related CC evaluations. This is noteworthy in relation to management strategies, given that all patients treated with ICI suffer from advanced cancer, and thus, unnecessary colonoscopy examinations should be avoided.

The National Comprehensive Cancer Network guidelines recommend that PSL, infliximab, or vedolizumab should be considered as treatment options for irAE colitis, in addition to symptomatic therapy and the suspension of ICI treatments.33 Alternatively, PSL, azathioprine, or mercaptopurine are considered acceptable for treating T-CC, in conjunction with symptomatic therapy and the discontinuation of related drugs.19 Anti-PD-1-related CC, which shows characteristics of both irAE colitis and T-CC, requires the withdrawal of suspected drugs in mild cases and systemic administration of PSL in severe cases. Thus, consultations with clinical oncologists are essential for the treatment of anti-PD-1-related CC and chemotherapy maintenance.

In this study, all patients who developed CC following anti-PD-1/PD-L1 treatment had a recent history of PPI usage. Notably, patient #8 showed no endoscopic findings before the ICI treatment. However, when this patient experienced severe diarrhea after the ICI treatment, a second colonoscopy showed mild mucosal cloudiness and linear erosion. We assume that the PPI-induced occult mucosal changes in the “first attack,” and the ICI elicited symptomatic diarrhea in the “second attack” contributed to complete the manifestation of anti-PD-1-related CC. Hughes et al. reported that seven out of 13 patients with microscopic colitis after an ICI treatment had previously taken PPI medications.36 Another report also showed that PPI administration after ICI treatment resulted in CC.37 Thus, the mechanism underlying anti-PD-1-related CC may involve immunological acceleration by anti-PD-1/PD-L1 antibodies in combination with PPI-induced intestinal changes, including intestinal dysbiosis or mucosal barrier weakness.

The limitations of this study include the single-center model and small number of cases. Moreover, the target patients were limited to those who were referred to our department for gastroenterology investigations. Future studies should be performed with patients from multiple centers.

In conclusion, anti-PD-1/PD-L1 treatments can cause anti-PD-1-related CC in patients treated with PPIs. The features of anti-PD-1-related CC include mild mucosal changes that are visible with endoscopy, regardless of
elevated FC levels, and a lack of intestinal wall thickening on CT images. A histological assessment is essential for a diagnosis of anti-PD-1-related CC. In this study, the histological features included predominant infiltration of CD8+ cells into the lamina propria and crypts, along with a subepithelial collagen band. The anti-PD-1-related CC diagnosis allowed us to suspend the PPI administration while continuing chemotherapy. Therefore, we emphasize that a histological evaluation of biopsy specimens is crucial for patients with diarrhea after an ICI treatment, regardless of the severity of the endoscopic findings. We recommend that CC be considered as a differential diagnosis for patients with diarrhea during ICI treatments. Appropriate irAE assessments will contribute to maintaining each patient’s quality of life.

ACKNOWLEDGMENTS
We would like to thank all clinical oncologists at Hirosaki University Hospital and Wiley Editing Services (https://wileyeditingservices.com/en/) for English language editing.

CONFLICT OF INTEREST
The authors have declared no conflict of interest.

ETHICS STATEMENT
This study was approved by the ethics committee of Hirosaki University School of Medicine (No.2018-1152) and conducted in accordance with the Declaration of Helsinki.

FUNDING INFORMATION
None.

ORCID
Hidezumi Kikuchi ⓜ
https://orcid.org/0000-0002-5163-9563
Yasuhsa Murai ⓛ
https://orcid.org/0000-0002-3305-1248
Daisuke Chinda ⓜ
https://orcid.org/0000-0003-1690-5923

REFERENCES
1. Schadendorf D, Wolchok JD, Hodi FS et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J Clin Oncol 2017; 35: 3807–14.
2. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: Case series and appraisal of “immunomodulatory gastroenterocolitis”. Histopathology 2017; 70: 558–67.
3. Wang Y, Abu-Stieh H, Mao E et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018; 24: 1695–705.
4. Kubo K, Kato M, Mabe K. Nivolumab-associated colitis mimicking ulcerative colitis. Clin Gastroenterol Hepatol 2017; 15: A35–6.
5. Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol 2017; 15: e80–1.
6. Bertha M, Bellaguarda E, Kuzel T, Hanauer S. Checkpoint inhibitor-induced colitis: A new type of inflammatory bowel disease? ACG Case Rep J 2017; 4: e112.
7. Kikuchi H, Sakuraba H, Akemoto Y et al. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Immunol Med 2019; 42: 39–44.
8. Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: Diagnostic utility of upper gastrointestinal biopsies. Histopathology 2020; 76: 233–43.
9. Baroudjian B, Lourenco N, Pagès C et al. Anti-PD-1-induced collagenous colitis in a melanoma patient. Melanoma Res 2016; 26: 308–11.
10. Janela-Lapert R, Bouteiller J, Deschamps-Huvier A, Duval-Moeste AB, Joly P. Anti-PD-1-induced collagenous colitis in metastatic melanoma: A rare severe adverse event. Melanoma Res 2020; 30: 603–5.
11. Calvani J, Elia R, Battistella M et al. An unusual digestive complication under anti-PD-1 (pembrolizumab). Ann Pathol 2020; 40: 320–3. French.
12. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncol 2016; 2: 1346–53.
13. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet] [cited 2020 Dec 31]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
14. Tanaka M, Saito H, Fukuda S, Sasaki Y, Munakata A, Kudo H. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: Measurement of validity Scand J Gastroenterol 2000; 35: 281–6.
15. Chen JH, Pezouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 2017; 41: 643–54.
16. Stahl E, Roda G, Dobryan A et al. Collagenous colitis is associated with HLA signature and shares genetic risks with other immune-mediated diseases. Gastroenterology 2020; 159: 549–61.e8.
17. Liu Q, Harpaz N. Expression profiling of inflammatory and immunological genes in collagenous colitis. J Crohns Colitis 2019; 13: 764–71.
18. Carstens A, Dicksved J, Nelson R et al. The gut microbiota in collagenous colitis shares characteristics with inflammatory bowel disease-associated dysbiosis. Clin Transl Gastroenterol 2019; 10: e00065.
19. Pardi DS. Diagnosis and management of microscopic colitis. Am J Gastroenterol 2017; 112: 78–85.
20. Tong J, Zheng Q, Zhang C, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 265–76.
21. Keszthelyi D, Jansen SV, Schouten GA et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: A case-control study. Aliment Pharmacol Ther 2010; 32: 1124–8.
22. Soulayre E, Lepage P, Colombel JF et al. Enterocolitis due to immune checkpoint inhibitors: A systematic review. Gut 2018; 67: 2056–67.
23. Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359: 97–103.
24. Dubin K, Callahan MK, Ren B et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7: 10391.
25. Marthey L, Mateus C, Mussini C et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016; 10: 395–401.
26. Collins M, Michot JM, Danlos FX et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017; 28: 2860–5.
27. Bavi P, Butler M, Serra S, Chetty R. Immune modulator-induced changes in the gastrointestinal tract. Histopathology 2017; 71: 494–6.
28. Coutzac C, Adam J, Soulaurue E et al. Colon immune-related adverse events: Anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis 2017; 11: 1238–46.
29. Geukes Foppen MH, Rozeman EA, van Wilpe S et al. Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management. ESMO Open 2018; 3: e000278.
30. Yanai S, Nakamura S, Kawasaki K et al. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients. Dig Endosc 2020; 32: 616–20.
31. Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol 2019; 10: 17–28.
32. Göransson C, Kumawat AK, Hultgren-Hörngvist E et al. Immuno-histochemical characterization of lymphocytes in microscopic colitis. J Crohns Colitis 2013; 7: e434–42.
33. Thompson JA, Schneider BJ, Brahmer J et al. NCCN Guidelines insights: Management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw, 2020; 18: 230–41.
34. D’Angelo F, Felley C, Frossard JL. Calprotectin in daily practice: Where do we stand in 2017? Digestion 2017; 95: 293–301.
35. Wildt S, Nordgaard-Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007; 19: 567–74.
36. Hughes MS, Molina GE, Chen ST et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019; 7: 292.
37. Yanai S, Nakamura S, Kawasaki K et al. Immune checkpoint inhibitor-induced colitis. Stomach Intest 2019; 54: 1751–6. (in Japanese).